换一批The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.
作者：
医学主题词
青少年(Adolescent);成年人(Adult);年龄分布(Age Distribution);老年人(Aged);老年人, 80以上(Aged, 80 and over);脑缺血(Brain Ischemia);双盲法(Double-Blind Method);用药计划表(Drug Administration Schedule);女(雌)性(Female);纤维蛋白溶解药(Fibrinolytic Agents);人类(Humans);输注, 静脉内(Infusions, Intravenous);男(雄)性(Male);中年人(Middle Aged);重组蛋白质类(Recombinant Proteins);二级预防(Secondary Prevention);疾病严重程度指数(Severity of Illness Index);卒中(Stroke);血栓溶解疗法(Thrombolytic Therapy);组织型纤溶酶原激活物(Tissue Plasminogen Activator);治疗结果(Treatment Outcome);青年人(Young Adult)
DOI
10.1016/S0140-6736(12)60768-5
PMID
22632908
发布时间
2025-05-29
基金项目
G1002605/MRC_/Medical Research Council/United Kingdom
G0400069/MRC_/Medical Research Council/United Kingdom
G0902303/MRC_/Medical Research Council/United Kingdom
G0800803/MRC_/Medical Research Council/United Kingdom
MC_G1002455/MRC_/Medical Research Council/United Kingdom
CSO_/Chief Scientist Office/United Kingdom
EME 09-800-15/MRC_/Medical Research Council/United Kingdom
- 浏览168
Lancet (London, England)
2352-63页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
